Researchers have reported a significant breakthrough in the global fight against gonorrhoea, identifying a key protein that could lead to the development of both a new vaccine and a novel class of antibiotics.
The study, published in PLOS Pathogens and shared with the Ghana News Agency, explains how the bacterium Neisseria gonorrhoeae—responsible for gonorrhoea—evades the body’s natural immune system. The discovery provides scientists with a new and promising target for therapeutic intervention, especially as antibiotic resistance continues to rise.
Gonorrhoea remains one of the most common sexually transmitted infections worldwide, with an estimated 78 million new infections recorded each year. Health experts warn that the infection is often silent, particularly in women, where up to half of cases may show no symptoms. Despite this, untreated infections can result in severe reproductive health complications, including pelvic inflammatory disease, infertility, ectopic pregnancy, miscarriage, and premature delivery. Newborns exposed during childbirth also face a high risk of blindness.
The urgency for new treatment options has intensified as Neisseria gonorrhoeae continues to develop resistance to nearly all available antibiotics, making it a growing “superbug” threat. Reports of treatment failures have increased, raising global public health concerns.
Leading the research, Oregon State University researcher Aleksandra Sikora and her team, in collaboration with scientists from the Uniformed Services University of the Health Sciences, identified a previously unknown protein known as SliC (surface-exposed lysozyme inhibitor of c-type lysozyme). This protein enables the bacterium to neutralize lysozymes—enzymes that form a critical part of the body’s first line of defense by breaking down bacterial cell walls.
Through laboratory studies and animal models, researchers demonstrated that SliC is essential for bacterial survival and colonisation. When this protein is disrupted, the bacterium’s ability to establish infection is significantly reduced.
“This is the first time an animal model has been used to confirm the role of a lysozyme inhibitor in gonorrhoea infection,” Dr. Sikora said, describing the findings as highly encouraging.
Scientists believe that targeting the SliC protein could weaken the bacterium and restore the body’s natural defenses, paving the way for innovative treatments and preventive vaccines. As resistance to existing drugs continues to grow, this discovery marks a critical step toward controlling and eventually reducing the global burden of gonorrhoea.
Source: Ministry of Health
